USANA Health Sciences (USNA) Set to Announce Earnings on Tuesday

USANA Health Sciences (NYSE:USNA) is set to issue its quarterly earnings data after the market closes on Tuesday, April 30th. Analysts expect the company to announce earnings of $0.69 per share for the quarter. USANA Health Sciences has set its FY 2024 guidance at 2.400-3.000 EPS.Parties that wish to listen to the company’s conference call can do so using this link.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, February 6th. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.35. The firm had revenue of $221.08 million for the quarter, compared to analysts’ expectations of $206.70 million. USANA Health Sciences had a net margin of 6.93% and a return on equity of 13.49%. On average, analysts expect USANA Health Sciences to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

USANA Health Sciences Trading Up 0.2 %

NYSE USNA opened at $44.23 on Tuesday. The company’s 50-day moving average price is $47.51 and its 200-day moving average price is $49.05. The stock has a market cap of $850.99 million, a PE ratio of 13.40, a PEG ratio of 1.35 and a beta of 0.91. USANA Health Sciences has a 12 month low of $42.59 and a 12 month high of $69.60.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. StockNews.com upgraded shares of USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Friday, January 12th. DA Davidson dropped their target price on shares of USANA Health Sciences from $53.00 to $48.00 and set a “neutral” rating on the stock in a report on Thursday, February 22nd.

Insiders Place Their Bets

In other USANA Health Sciences news, insider Robert A. Sinnott sold 3,945 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $46.55, for a total transaction of $183,639.75. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, insider David Mulham Mulham sold 4,311 shares of the firm’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $47.76, for a total value of $205,893.36. Following the sale, the insider now directly owns 7,825 shares in the company, valued at approximately $373,722. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Robert A. Sinnott sold 3,945 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $46.55, for a total transaction of $183,639.75. The disclosure for this sale can be found here. Insiders have sold a total of 24,807 shares of company stock worth $1,200,791 in the last three months. Corporate insiders own 0.33% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.